semaglutide heart failure trial in with preserved ejection fraction: The STEP-HFpEF tested the hypothesis that treatment with semaglutide can significantly improve symptoms, physical limitations and exercise function, in addition to weight loss Cardiovascular risk reduction with once-weekly

I believe that the notion of oral GLP-1s being a net negative for Stevanato is pretty misguided, for several reasons

These treatments arent a onesizefitsall solution, but certain people tend to see the most significant benefits

Patients who do not respond adequately may increase to 1.25 mg per dose

This is remarkable for any pharmaceutical compound and reflects AOD 9604 highly targeted mechanism that affects fat cells without interfering with other physiological systems

Why you should not adjust your own dose It can be tempting to preemptively reduce your levothyroxine when starting tirzepatide, especially after reading about the interaction